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Abstract
Background: Range of motion is the most frequently reported measure used in practice to evaluate outcomes.
A goniometer is the most reliable tool to assess range of motion yet, the lack of consistency in reporting prevents
comparison between studies. The aim of this study is to identify how range of motion is currently assessed and
reported in Dupuytren’s disease literature. Following analysis recommendations for practice will be made to enable
consistency in future studies for comparability. This paper highlights the variation in range of motion reporting in
Dupuytren’s disease.
Methods: A Participants, Intervention, Comparison, Outcomes and Study design format was used for the search
strategy and search terms. Surgery, needle fasciotomy or collagenase injection for primary or recurrent Dupuytren’s
disease in adults were included if outcomes were monitored using range of motion to record change. A literature
search was performed in May 2013 using subject heading and free-text terms to also capture electronic publications
ahead of print. In total 638 publications were identified and following screening 90 articles met the inclusion criteria.
Data was extracted and entered onto a spreadsheet for analysis. A thematic analysis was carried out to establish any
duplication, resulting in the final range of motion measures identified.
Results: Range of motion measurement lacked clarity, with goniometry reportedly used in only 43 of the 90 studies,
16 stated the use of a range of motion protocol. A total of 24 different descriptors were identified describing range of
motion in the 90 studies. While some studies reported active range of motion, others reported passive or were unclear.
Eight of the 24 categories were identified through thematic analysis as possibly describing the same measure, ‘lack of
joint extension’ and accounted for the most frequently used.
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Conclusions: Published studies lacked clarity in reporting range of motion, preventing data comparison and
meta-analysis. Percentage change lacks context and without access to raw data, does not allow direct comparison of
baseline characteristics. A clear description of what is being measured within each study was required. It is recommended
that range of motion measuring and reporting for Dupuytren’s disease requires consistency to address issues
that fall into 3 main categories:-
 Definition of terms
 Protocol statement
 Outcome reporting
Keywords: Dupuytren’s disease, Range of motion, Assessment, Outcome measure, Recommendations
Background
Change in hand function should be assessed using a
combination of physical measures and questionnaires [1].
The lack of extension of the hand is the reason why pa-
tients with Dupuytren’s disease often seek advice [2] and
therefore a measurement that captures this should be
included in evaluation of Dupuytren’s disease. Range of
motion (ROM) has customarily been used to evaluate
hand function [3, 4] and has been defined as the most
commonly used physical outcome measure in Dupuytren’s
disease literature [5]. Using a goniometer to assess ROM
is regarded as an objective and reliable measure [6], there-
fore an obvious assessment tool for Dupuytren’s disease.
Bindra [7] highlights the importance of developing and
adhering to protocols for assessments such as goniom-
etry for reliable measurement to be taken. However, it
has recently been reported that there is a continued lack
of consistency with the variation in measures used in
ROM reporting precluding comparison between studies
[5] and thus warrants further analysis. Post et al [8] re-
cently acknowledged the paucity of high level evidence
in surgical literature and recommended the development
of higher methodological and reporting standards to as-
sist this issue. Giladi and Chung [3] have also reported
concerns in deficiencies associated with outcomes meas-
urement with lack of transparency and incomplete
reporting of data also raised as a concern [9].
This discussion paper aims to identify and review
the diversity of assessment and reporting of ROM in
Dupuytren’s disease literature using systematic processes
following PRISMA guidelines [10] (Additional file 1). The
aim was not to evaluate the quality of the interventions
used. Following analysis of the data a minimum set of
ROM measurements are identified and recommendations
for future practice made.
Range of motion is the most frequently reported meas-
ure used in practice to evaluate outcomes. A goniometer
is the most reliable tool to assess range of motion yet,
the lack of consistency in reporting prevents comparison
between studies. The aim of this study is to identify
how ROM is currently assessed and reported in
Dupuytren’s disease literature. Following analysis rec-
ommendations for practice will be made to enable
consistency in future studies for comparability. This
paper highlights the variation in range of motion
reporting in Dupuytren’s disease.
Methods
A Participants, Intervention, Comparison, Outcomes and
Study design (PICOS) format was used for the search
strategy and search terms (Table 1). Publications were
suitable for inclusion if published in the English language
within the last 20 years.
A literature search was performed in May 2013 using
subject heading and free-text terms as reported in
Table 1. Ovid Medline, Embase and CINAHL (via EBS-
COHost) databases were searched from 1992 to May
2013. In order to capture electronic publications ahead
of print and not included in Ovid Medline, PubMed was
searched from 2011 to May 2013. All searches were lim-
ited to publications in English and results were imported
into in Refworks resulting in 638 publications after
removal of duplicates (Fig. 1).
Using the review protocol, publications for this cri-
tique were suitable for inclusion if participants had re-
ceived a surgical treatment, percutaneous fasciotomy or
collagenase injection for Dupuytren’s disease, published
in the English language and reported ROM outcomes
that permitted analysis of the data. The follow-up period
for post-intervention monitoring for included publications
was not limited. Case studies and conference papers
were excluded. All 638 titles/abstracts were independently
screened by both authors using inclusion and exclusion
criteria. If agreement was not initially reached both
authors discussed the study to achieve a consensus of
opinion. Full text was obtained for 101 publications that
met the inclusion criteria. Using the study eligibility
screening tool 11 publications were excluded as data did
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not enable analysis. In total 90 articles met the inclusion
criteria and data extracted independently using the ROM
reporting extraction form.
A Microsoft Excel (Microsoft, Seattle) spreadsheet
was used to collect and tabulate data on intervention,
population and ROM measure/s for each included study.
The spreadsheet collected data on study design, reported
ROM measure and if the method of measurement
was described, identification if active or passive mo-
tion was recorded, if measurements were taken using
Table 1 Search strategy and Search terms using PICOS analysis
Definition Main Search Terms for Ovid Medline Strategy (Subject heading (/)
and free text terms ($ indicates truncation; adj3 finds terms within
2 words of each other)
Participants Persons with Dupuytren’s disease Dupuytren’s contracture/or dupuytren $
Intervention Surgical treatment including percutaneous or
collagenase injection for Dupuytren's disease of
the hand.
Exp surgical procedures, operative/or surg$ or fasciectom$
or fasciotom$ or dermofasciectom$ or open palm or mccash
or aponeurectom$ or aponeurotom$.mp. Injections/or
injections, Intralesional/or inject$ or collagenases/ or
microbial collagenases/or collagenase$
Comparisons Not applicable
Outcomes Range of motion/movement Exp treatment outcome/or outcome assessment (healthcare)/or
outcome$ or hand$ adj3 function$/or exp range of motion,
articular/or range of motion or follow-up studies/or disability
evaluation/or disab$ adj3 eval$ or disab adj3 assess$ or efficac$
Study design All Included:-
Screen search results manually to include RCT’s and
non-randomised controlled clinical trials, prospective
and retrospective case series. Excluded:-Case studies
and conference papers.
Screened using study eligibility tool
Fig. 1 Study Search and Selection process, PRISMA flow diagram
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a goniometer, whether a goniometry protocol was used,
any classification or grading system reported and if
hyperextension was reported how it was addressed in
calculations.
The descriptions of the included articles ROM out-
come variables were recorded verbatim for categories to
be identified. A thematic analysis was carried out on the
categories to establish any duplication, resulting in the
final ROM measures identified.
Results
Study design
From the 90 included studies [11–100] 13 (14.4 %) were
randomised controlled trials. The remainder of the
studies were case series or cohort studies. An additional 26
(28.9 %) reported results from prospective studies and 31
(34.4 %) reported retrospectively. Two studies (2.2 %) used
a combined prospective and retrospective design while the
remaining 18 studies (20.0 %) were categorised as ‘unclear’
as it was not possible to ascertain if the design was pro-
spective or retrospective. As the aim was to identify ROM
measures used rather than to compare results of treatment
further analysis of the overall quality of individual studies
was not performed. The ROM reporting measure was
synthesised at outcome level, as reported below.
Goniometer and protocol use
Goniometry was explicitly used to measure ROM in 43
of the 90 studies and it was unclear how ROM was
assessed in the remaining 47 studies, although results
were reported in degrees. Of the 43 studies that reported
use of a goniometry 16 stipulated a ROM protocol [12,
21, 23, 32, 38, 44, 48, 51, 53, 54, 63, 64, 68, 81, 99, 100].
It was unclear if a ROM protocol was used for the
remaining 27 (62.8 %) studies that reported using a goni-
ometer. In total 128 ROM data sets were reported from
the 90 studies (Table 2) and in over 60 % of these it was
unclear if measurements had been taken actively or pas-
sively. Of the 16 studies that reported using a goniom-
eter protocol only 4 studies reported information about
the measurement assessment position [32, 64, 68, 81].
Two studies [32, 81] reported placing the metacarpopha-
langeal (MCP) joint in flexion to assess passive proximal
interphalangeal (PIP) joint extension and 2 studies
[64, 81] assessed active PIP extension with the MCP
flexed. A further study [68] stated the position of the
wrist and hand.
Reported ROM measures
Nine studies used the maximum number of 3 ROM
measures to report their results [24, 28, 30, 41, 42, 44,
50, 89, 96] Sixty one studies used 1 ROM measure and
20 used 2 ROM measures (Table 2).
Of the 61 studies reporting only one measure 9 studies
[18, 25, 52, 62, 81, 86, 90–92] recorded passive motion
only. Additionally two studies [48, 64] who used one
measure reported both active and passive motion.
Terminology
The thematic analysis identified 24 ROM outcome
categories. Further scrutiny revealed that 8 of the 24
described the same measure and for the purpose of this
study were combined as a category describing ‘lack of
extension’ (Fig. 2) resulting in a total of 17 categories.
No study reported the use of more than one of these
eight ‘Lack of joint extension’ terms. This supports the
suggestion that the 8 categories describe the same meas-
ure. The resulting category ‘Lack of joint extension’ was
used by 34 of 61 studies reporting one ROM measure,
12 of the 20 studies using 2 measures and all 9 of the
studies using 3 ROM measures.
The 17 categories illustrate the varied use of ROM
outcome measures used in Dupuytren’s disease publica-
tions (Fig. 3).
Fixed flexion deformity (FFD) or fixed flexion contrac-
ture (FFC) was reported in 5 studies [33, 34, 36, 66, 73].
The definition and calculation of FFD/FFC varied.
Percentage change as a measure was used in 19 studies
[17, 28, 30, 40–44, 50–52, 59, 66–68, 90, 91, 96, 99] with 3
reporting it as their sole outcome measure [52, 90, 91].
Four studies [20, 39, 45, 57, 58, 78, 89, 98, 99] presented
data as differences or graphs with 2 authors using
their chosen ROM outcome as their only measure
[20, 39, 45, 57].
Hyperextension
Hyperextension was included in 11 of the studies
[11, 33, 50, 53, 66, 72, 75, 77, 80, 83, 89]. The descrip-
tion of how this was recorded and analysed varied be-
tween studies. Three studies reported hyperextension as a
negative value [33, 50, 80] of which two [33, 80] sub-
tracted and one added [50] hyperextension to the ROM
calculation. Hyperextension measurement was included in
results in four studies [11, 66, 77, 83] without prior de-
scription in the text or discussion on how hyperextension
Table 2 Distribution of papers reporting one or more ROM measure
Frequency (n=)
1 ROM measure reported [11–16, 18–21, 25–27, 29, 31–39, 45–49, 52, 55–57, 60–64, 70–74, 76, 79–88, 90–95, 97, 100] 61
2 ROM measures reported [17, 22, 23, 40, 43, 51, 53, 54, 58, 59, 65–69, 75, 77, 78, 98, 99] 20
3 ROM measures reported [24, 28, 30, 41, 42, 44, 50, 89, 96] 9
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Fig. 2 The identified 8 categories demonstrating the varied terminology for ‘lack of joint extension’ and frequency
Fig. 3 Variation of measures used by description (n = 17) with the number of measures used for each study
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was analysed. Three studies [72, 75, 89] indicated that
hyperextension was included in a composite ROM
measure with only one [75] stating how hyperextension
was calculated within the composite measure. One publi-
cation clearly described how hyperextension was recorded
and analysed as a zero value [53].
Grading systems & composite measures
Tubiana grading system assigns a score to the extension
deficit of a digit by summing the total deficit angles of
the MCP, PIP and distal interphalangeal (DIP) [101,
102]. Tubiana grading system was reported both pre and
post operatively in 7 studies [19, 50, 55, 65, 72, 86, 93].
One study [50] used Tubiana in addition to another
ROM measure, the remaining 6 studies [19, 55, 65, 72,
86, 93] used it as their sole measure.
Total active motion (TAM) is described by the American
Society for Surgery of the Hand (ASSH) as the sum of ac-
tive MCP, PIP and DIP arc of motion in degrees of an indi-
vidual digit [6]. This calculation can then be compared to
the TAM of the contralateral hand or the norm of
260 degrees. Five studies [23, 24, 48, 75, 89] reported
using TAM methodology. Four [23, 24, 75, 89] of the
5 studies reporting Total Motion recorded active
measurements supplemented with one or more ROM
measures. One study used Total Motion as their only
measure recording both active and passive motion
[48]. Two of the 5 studies reporting TAM described
their goniometer protocol [23, 48].
Other grading systems used were Thomine improve-
ment coefficient [57, 89], Honner classification [58] and
Strickland and Glogovac method [78].
Discussion
It is reported that ROM is the most commonly reported
outcome measure for Dupuytren’s disease [5] however it
is clear from reviewing the literature that there is confu-
sion regarding what to measure, method of measure and
how to describe and report it. The study designs were
retrospective (31 publications) or unclear (18 publications)
for 49 of the 90 studies. Future publications should focus
on clearly reporting prospective data using well-designed
studies. This review was limited to publications in the
English language and to studies that reported comparable
ROM data to meet the aim of this review. The quality
of the ROM method and the presentation of the results
are now critiqued to identify robust ROM methods
for future studies.
From reviewing the literature a number of concerns
were identified regarding assessment and reporting of
data that will now be discussed in turn.
 Use of terminology
 Measurement protocol
 Hyperextension reporting and analysis
 Inconsistencies in Total Active Motion
 Use of Tubiana Grading system
 Percentage change to demonstrate change
 Other methods
Use of terminology
There were 8 ROM descriptors that appeared to describe
the same measure (see Fig. 2). While this may appear to
be semantics, lack of published protocols necessitates in-
terpretation by the reader leading to potential ambiguity.
For clarity authors should provide a clear protocol to
support their chosen method.
From the literature reviewed it is suggested that the
terminology currently in use is varied. From the the-
matic analysis 24 Dupuytren’s disease ROM categories
were found. With the absence of measurement defin-
ition, 8 of these ROM categories appeared to be report-
ing the same measure (Lack of joint extension) as
illustrated in Fig. 2.
There are inconsistencies in terminology within stud-
ies; the use of ‘contracture’ and ‘deformity’ was used
interchangeably [76] and pre-operative ‘contracture’ and
post-operative ‘joint extension’ [79]. Watt [95] clearly
defined what they measured as ‘degree of extensor lag’
yet presented results as ‘joint contracture’. Another study
[62] reported mean extension deficit at base line and the
mean extension deficit gain post treatment. This lack of
consistency causes uncertainly when comparing results
between studies.
The term ‘fixed’ in FFD/FFC suggests an arthrodesed
joint, unable to extend or flex from its fixed position.
However, in the studies reviewed the term ‘FFD’/FFC
has been identified in some of the studies to describe
movable joints [33, 36, 44, 54, 66, 73, 98]. It is therefore
anticipated that some authors referred to a joint with
limited maximum extension rather than an arthrodesed
joint. Only one study [34] described how FFC was calcu-
lated. This highlights the need for an agreed FFD/FFC
definition to enable consistency. Until this is achieved
future publications should clearly define what is meant
by the term ‘fixed’. Authors need to be more aware of
the choice of terminology to assist clearer communica-
tion of their findings.
Measurement protocol
As goniometry has been previously acknowledged as the
most frequent outcome measure [5] it can therefore be
argued that a ROM protocol should be provided as
standard in publications to aid transparency.
The position of the MCP joint can influence the max-
imum motion achieved at the PIP joint, as reported by
Tonkin et al [103]. This also has the added benefit of
minimizing the effect of dynamism as described by
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[104]. While passive motion is useful to record changes
resulting from surgery, active motion may illustrate the
functional gain. To demonstrate a comprehensive ROM
of the Dupuytren’s hand we advocate the inclusion of
active and passive digital flexion and extension of each
joint, with the additional measure of active PIP exten-
sion with the MCP held in flexion.
The lack of clarity regarding if a joint was assessed ac-
tively or passively was unexpectedly high and illustrates
the difficulty to accurately compare findings. This prob-
lem was also highlighted in a recent Cochrane review
[4]. Both active and passive motion is important to
establish severity in Dupuytren’s disease, improvement
and potential for gain and those studies reporting both
[77, 97] may provide deeper insight into the potential
functional use of the hand.
The use of a goniometer in measuring ROM also
highlights the need to define zero degrees. Witthaut
[99] stated zero degrees on the goniometer as neutral
whereas Lee [58] described full extension as 180 degrees.
Usual practice defines full joint extension as zero degrees
but either is acceptable when described.
Change in flexion may suggest functional impairment
and was reported in only two studies [77, 96]. Weinzweig
[96] reported active flexion pre and post-operatively con-
cluding that flexion deteriorated. It is important that
flexion is assessed and reported pre and post intervention
to establish if extension has been achieved at the expense
of flexion. Van Rijssen [90, 91] reported post-operative
flexion deficit at 6 weeks with distance from palm to distal
palmar crease but no pre-operative data, preventing
analysis of change. It should not be presumed that
flexion at baseline is unaffected.
Hyperextension reporting and analysis
It is usual clinical practice to record hyperextension of a
joint to document flexibility. Compensatory hyperexten-
sion of the MCP can be associated with an extension
deficit at the PIP joint [89]. It may therefore be assumed
that it is important to report any joint hyperextension as
a potential indicator for biomechanical change.
How hyperextension is addressed in calculating
ROM remains an issue. The difficulty arises when
hyperextension of a joint is included in ROM analysis
as it may produce misleading data. Including hyper-
extension when calculating MCP motion increases
overall arc of motion [75]. Some authors considered
hyperextension as a negative value in their calculation
subtracting the hyperextension from the total digit
extension deficit, producing a lower deficit [33, 80].
Conversely, adding hyperextension to post-operative
gain at individual joints suggests an enhanced improve-
ment [50]. Jerosch-Herold [53] recorded hyperextension,
where present, and converted hyperextension to zero for
TAE and TAF analysis purposes, thus avoiding problems
highlighted above.
Where other authors expressed hyperextension denot-
ing with a minus sign Denkler [31] used this annotation
to express a lack of extension. In this case a pre-
operative extension deficit is reported as a minus figure
(e.g. -75). When a 45 degree improvement is recorded
(therefore still short of full extension) this is illustrated
as a smaller negative value (e.g. -30) differing to other
studies. Universal agreement on the use of positive and
minus values for extension and hyperextension record-
ing and calculation is required to avoid confusion. An
alternative solution is the use of H following the degrees
measured, to record hyperextension e.g. 15H.
Inconsistencies in total active motion
A disadvantage of TAM calculation means that change
in any particular joint cannot be identified unless sup-
plemented with additional information for transparency.
Only 2 studies [24, 48] reported calculating TAM as
described by ASSH [6]. In contrast one study interpreted
TAM as the arc of motion at each of the MCP and PIP
joints [89] while another reported the use of TAM by
combining the calculations of three digits (middle, ring
and little) to provide an overall figure [23]. This com-
bined TAM precludes comparison with other studies or
analysis of the data for each joint and digit. The varied
interpretations of TAM demonstrates inconsistencies
further highlighting concerns. It is recommended that
authors correctly use the originally described method of
calculation in the future.
Transparent reporting of ROM was provided by Roush
[75] in tables to clearly detail extension and flexion of
each joint for each patient. However, hyperextension was
used in the TAM calculation. An increase in hyperexten-
sion can be miss-interpreted as ROM gain [6] but may
also conceal a decrease at another joint. While TAM has
benefits in reporting the arc of motion it should always
be supplemented with additional ROM measures for
each joint as demonstrated by Roush [75]. As the PIP
joint responds differently to the MCP joint in the disease
and treatment process detailing the results of each joint
individually will also enable further comparison.
Shaw [78] analysed ROM data using another composite
measure [105] which sums the MCP and PIP (i.e. excludes
the DIP). This has the advantage of only including the 2
joints primarily affected by Dupuytren’s disease, but ignores
the secondary changes that may occur at the DIP joint.
Providing the active flexion and extension measurements
of all three joints is therefore the preferred option.
Use of tubiana grading system
Tripoli [86] clearly reported using passive motion in cal-
culating the digital Tubiana score. Referencing sources
Pratt and Ball BMC Musculoskeletal Disorders  (2016) 17:20 Page 7 of 11
demonstrate implied application of a given methodology
however, stating implicitly how it was followed reassures
the reader. Hovius [50] reports calculating the Tubiana
score by summing the MCP and PIP joints and does not
state the inclusion of the DIP. Beaudreuil [19] calculates
a Tubiana score taking the whole hand into consider-
ation. This illustrates the variations in interpretation of
the Tubiana methodology.
Tubiana calculation has been modified over time since
its original conception [101, 102]. While this demonstrates
development of the measure it also poses challenges for
analysis with authors using a variety of published versions
that may preclude comparison. Six of the 7 studies sup-
ported their selected Tubiana methodology with one of
five references. There are inherent flaws when calculating
Tubiana. As previously discussed including hyper exten-
sion in a composite calculation raises issues with analysis.
It is unclear from the 7 studies [50, 55, 65, 72, 86, 93] how
hyperextension was addressed. Additionally this is com-
pounded with Tubiana [102] stating that the degree of
hyperextension at the DIP joint is added to the total
flexion deformity (i.e. extension deficit) of the other joints
but is not supported with the example calculation.
A further difficulty with the Tubiana calculation is the
assignment to a corresponding stage. This is apparent
when the correct calculation falls between two ROM
bands (e.g. 45 degrees at the top of stage 1 or bottom of
stage 2 and 90 degrees in stage 2 or 3). The ROM bands
for the Tubiana stages are clearly stated in 3 studies
[55, 72, 86], however the authors do not state how
they dealt with calculations that could be assigned to
either stage. Improvement of ROM may occur within a
band yet the measure lacks sensitivity to illustrate such.
The authors of this paper also argue that Tubiana calcu-
lations do not adequately describe at which joint a ROM
deficit occurs. This is illustrated by Vigroux [93] when the
figures report overall pre and post-operative Tubiana scores
yet do not identify if this equates an improvement for the
individual patient or trends in movement.
Tubiana was more often used as a method to grade
severity of Dupuytren’s disease at baseline [12, 18, 41,
47, 67, 69, 87, 90, 91] with other ROM measures used
pre and post intervention for comparative purposes. It is
therefore suggested that Tubiana is best used to identify
baseline disease severity or to stratify for analysis rather
than as an outcome measure.
Percentage change
Percentage change was used in 3 [52, 90, 91] studies as
their sole measure. Percentage change is arguably of lit-
tle value unless baseline data is presented for context.
For example a 90 % improvement in extension deficit
may be illustrated by one patient improving from 20 de-
grees extension deficit at baseline to 2 degrees while a
second patient improves from 80 to 8 degrees. The
second example gained the larger improvement (72
degrees), started further from zero degrees (desired
end point) and although the results share common
metrics their comparison lacks context. It is therefore
suggested that the use of percentage change is not
used as the sole outcome measure.
Other ROM analysis
Four studies presented results as the differences for their
chosen outcome measure [39, 45, 98, 99]. In presenting
differences, rather than the actual measurements for at
least one of the data sets, means that the pre or post
ROM cannot be established for comparison proposes.
One study presented data differences in graphs [39]
therefore preventing accurate data extraction. We would
recommend that future studies include at least one
tabled data set if reporting differences as results.
Four studies presented results using 3 other grading
systems Thomine improvement coefficient [57, 89], Honner
classification [58] and Strickland and Glogovac method
[78]. Only 1 study evaluated thumb angles using distance
measured in centimetres [20] (see Fig. 3).
Using an outcome measure not commonly used by
other studies presents difficulty when comparing results
for meta-analysis.
Table 3 Recommendations to improve ROM measuring and
reporting robustness in practice
Definition of terms
1. Agreement on terminology to report ‘lack of extension’ at a joint.
2. Agreed Fixed Flexion Deformity definition to enable consistency.
Protocol statement
3. Adherence to an agreed published ROM protocol to aid transparency
4. Zero or 180 degrees should be considered equivalent when describing
full extension for reporting and analysis if previously described.
5. Universal agreement is required on the use of positive or negative
values in hyperextension measurement for reporting and analysis.
Outcome reporting
6. Clear and consistent use of reporting active / passive ROM is required
for comparison of data.
7. Flexion should be assessed and reported pre and post intervention to
establish if extension was achieved at the expense of flexion.
8. When reporting composite measures (e.g. TAM, Tubiana) additional
ROM measures for each joint should be recorded to identify where
the change occurred.
9. Further clarity is required for Tubiana band definitions to avoid
overlapping.
10. Percentage change should not to be used as the sole outcome
measure without baseline data.
11. Outcomes presented as differences must be supported with at least
one tabled data set for accurate reporting.
12. ROM presented in graphs must be supported by data for accurate
reporting.
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Conclusion
Based on our findings we recommend that ROM meas-
uring and recording for Dupuytren’s disease requires
consistency to enable comparability of results in future
research. All studies should include active and passive
digital flexion and extension of each joint, with the
additional measure of active PIP extension with the
MCP held in flexion. The following points should also
be considered as recommended in Table 3.
We also encourage the use of standard terminology in
assessing Dupuytren’s disease to further define the ROM
assessment. It is suggested if the issues1-5 raised in
Table 3 are addressed by professional bodies (Definition of
term and Protocol Statement) it will assist in the develop-
ment of consistent procedures. Researchers and clinicians
can also play a part in improving the quality of Dupuytren’s
disease evidence by addressing points 6-12 highlighted in
Table 3. Together by addressing these issues ROM
outcomes in research can be improved which will provide
better quality evidence in future publications [3, 8, 9].
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